Ye et al. 2020a Current Opinion in Oncology. 33(1):87-94

Purpose of review
Despite the significant advances in EGFR- mutant nonsmall cell lung cancer (NSCLC), some challenges remain. One of the permanent and inevitable issues is the emergence of acquired resistance. Therefore, blocking the activation of EGFR pathway and overcoming drug resistance with novel agents are still in high demand. Here, we review the development of novel drugs in EGFR -mutant, advanced NSCLC, including targeting EGFR exon 20 insertion (EGFR20ins), and novel role of epidermal growth factor receptor, tyrosine kinase inhibitor (EGFR-TKIs) in early-stage NSCLC.
Recent findings
EGFR-TKIs as adjuvant therapy or neoadjuvant therapy in patients with early-stage NSCLC with EGFR -sensitizing mutations have shown promising efficacy. The resistance mechanisms of third-generation EGFR-TKIs can be divid…